ACADIA Pharmaceuticals Inc. (ACAD) Shares Sold by First Trust Advisors LP

First Trust Advisors LP lowered its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 29.5% in the fourth quarter, HoldingsChannel reports. The firm owned 4,138,725 shares of the biopharmaceutical company’s stock after selling 1,731,968 shares during the period. First Trust Advisors LP’s holdings in ACADIA Pharmaceuticals were worth $66,923,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Prudential Financial Inc. grew its position in ACADIA Pharmaceuticals by 8.3% during the fourth quarter. Prudential Financial Inc. now owns 12,449 shares of the biopharmaceutical company’s stock worth $201,000 after buying an additional 949 shares in the last quarter. Canada Pension Plan Investment Board grew its position in ACADIA Pharmaceuticals by 15.4% during the fourth quarter. Canada Pension Plan Investment Board now owns 97,300 shares of the biopharmaceutical company’s stock worth $1,573,000 after buying an additional 12,964 shares in the last quarter. Smith Asset Management Group LP acquired a new stake in ACADIA Pharmaceuticals during the fourth quarter worth about $188,000. TD Asset Management Inc. grew its position in ACADIA Pharmaceuticals by 36.8% during the fourth quarter. TD Asset Management Inc. now owns 147,249 shares of the biopharmaceutical company’s stock worth $2,381,000 after buying an additional 39,649 shares in the last quarter. Finally, Creative Planning grew its position in ACADIA Pharmaceuticals by 19.7% during the fourth quarter. Creative Planning now owns 35,658 shares of the biopharmaceutical company’s stock worth $577,000 after buying an additional 5,876 shares in the last quarter. Institutional investors own 93.07% of the company’s stock.

NASDAQ ACAD opened at $22.26 on Friday. ACADIA Pharmaceuticals Inc. has a 1-year low of $12.77 and a 1-year high of $32.53.

A number of equities research analysts recently weighed in on the company. BidaskClub downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. Zacks Investment Research downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 31st. Canaccord Genuity assumed coverage on ACADIA Pharmaceuticals in a research report on Monday, December 10th. They set a “hold” rating and a $23.00 target price on the stock. Cantor Fitzgerald set a $30.00 target price on ACADIA Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, November 7th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 1st. Seven analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. ACADIA Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $31.09.

In other ACADIA Pharmaceuticals news, Director Laura Brege sold 10,000 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Wednesday, January 9th. The stock was sold at an average price of $20.00, for a total transaction of $200,000.00. Following the sale, the director now directly owns 10,000 shares of the company’s stock, valued at $200,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bros. Advisors Lp Baker acquired 11,764,705 shares of the firm’s stock in a transaction on Friday, November 30th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $199,999,985.00. The disclosure for this purchase can be found here. 23.28% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.com-unik.info/2019/02/22/acadia-pharmaceuticals-inc-acad-shares-sold-by-first-trust-advisors-lp.html.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Recommended Story: How is the S&P 500 index different from the DJIA?

Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit